

研究成果の刊行に関する一覧表

書籍

著者氏名	論文タイトル名	書籍全体の 編集者名	書 籍 名	出版社名	出版地	出版年	ページ

雑誌

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Masato Nakai, Tsukasa Seya, Misako Matsumoto, Kunitada Shimotohno, <u>Naoya Sakamoto</u> , Hussein H Aly	The J6JFH1 strain of hepatitis C virus infects human B cells with low replication efficacy.	Viral Immunology		in press	2014
Chuma M, <u>Sakamoto N</u> , Nakai A, Hige S, Nakanishi M, Natsuizaka M, Suda G, Sho T, Hatakaka K, Matsuno Y, Yokoo H, Kamiyama T, Taketomi A, Fujii G, Tashiro K, Hikiba Y, Fujimoto M, Asaka M, Maeda S	Heat shock factor 1 accelerates hepatocellular carcinoma development by activating nuclear factor B/mitogen-activated protein kinase.	Carcinogenesis	35(2)	272-281	2014
Shen H, Yamashita A, Nakakoshi M, Yokoe H, Sudo M, Kasai H, Tanaka T, Fujimoto Y, Ikeda M, Kato N, <u>Sakamoto N</u> , Shindo H, Maekawa S, Enomoto N, Tsubuki M, and Moriishi K	Inhibitory Effects of Caffeic Acid Phenethyl Ester Derivatives on Replication of Hepatitis C Virus.	Plos One	8(12)	e82299	2013
Ohnishi S, Maehara O, Nakagawa K, Kameya A, Otaki K, Fujita H, Higashi R, Takagi K, Asaka M, <u>Sakamoto N</u> , Kobayashi M, Takeda H	Hypoxia-inducible Factors Activate CD133 Promoter through ETS Family Transcription Factors.	Plos One	8(6)	e66255	2013

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Kiyohashi K, Kakinuma S, Kamiya A, <u>Sakamoto N</u> , Nitta S, Yamanaka H, Yoshino K, Fujiki J, Murakawa M, Kusano-Kitazume A, Shimizu H, Okamoto R, Azuma S, Nakagawa M, Asahina Y, Tanimizu N, Kikuchi A, Nakauchi H, and Watanabe M.	Wnt5a Signaling Mediates Biliary Differentiation of Fetal Hepatic Stem/Progenitor Cells.	Hepatology	57(6)	2502-2513	2013
<u>Sakamoto N</u> :	NX-PVKA assay, a conventional but refined prognostic biomarker for Hepatocellular carcinoma.	Journal of Gastroenterol and Hepatol	28(5)	755-756	2013
Huang JT, Tseng CP, Liao MH, Lu SC, Yeh WZ, <u>Sakamoto N</u> , Chen CM, Cheng JC:	Hepatitis C virus replication is modulated by the interaction of non-structural protein NS5B and fatty acid synthase.	Journal of Virology	87(9)	4994-5004	2013
Oze T, Hiramatsu N, Mita E, Akuta N, <u>Sakamoto N</u> , Itoh Y, Izumi N, Nomura H, Hayashi N, Takehara T	A multi-center survey of re-treatment with pegylated interferon plus ribavirin combination therapy for patients with chronic hepatitis C in Japan.	Hepatology Res	43(1)	35-43	2013
<u>Kurosaki M</u> , Tanaka Y, Nishida N, <u>Sakamoto N</u> , Enomoto N, Matsuura K, Asahina Y, Nakagawa M, Watanabe M, Sakamoto M, Maekawa S, Tokunaga K, Mizokami M, Izumi N	Model incorporating the ITPA genotype identifies patients at high risk of anemia and treatment failure with pegylated- interferon plus ribavirin therapy for chronic hepatitis C.	J Med Virol	85(3)	449-458	2013
Kohjima M, Enjoji M, Yoshimoto T, Yada R, Fujino T, Aoyagi Y, Fukushima N, Fukuizumi K, Harada N, Yada M, Kato M, Kotoh K, Nakashima M, <u>Sakamoto N</u> , Tanaka Y, Nakamuta M	Add-on therapy of pitavastatin and eicosapentaenoic acid improves outcome of peginterferon plus ribavirin treatment for chronic hepatitis C.	J Med Virol	85(2)	250-260	2013

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Nitta S, <u>Sakamoto N</u> , Nakagawa M, Kakinuma S, Mishima K, Kusano-Kitazume A, Kiyohashi K, Murakawa M, Nishimura-Sakurai Y, Azuma S, Tasaka-Fujita M, Asahina Y, Yoneyama M, Fujita T, Watanabe M	Hepatitis C virus NS4B protein targets STING and abrogates RIG-I-mediated type-I interferon- dependent innate immunity	Hepatology	57(1)	46-58	2013
<u>坂本直哉</u>	肝炎ウイルス学 近年の進歩	診断と治療	101(9)	1283-1286	2013
<u>坂本直哉</u>	C型肝炎の近未来治療.	化学療法の領域	28(S-1)	1134-1140	2012
<u>坂本直哉</u>	C型肝炎治療薬 テラプレビル	薬局	63 (1)	123-128	2012
新田沙由梨, <u>坂本直哉</u>	NCV-NS4B 蛋白と IFN 発現計シグナル分子との分子間相互作用の解析	消化器と免疫	48	174-177	2011
Murata K, <u>Sugiyama M</u> , Kimura T, Yoshio S, Kanto T, Kirikae I, Saito H, Aoki Y, Hiramane S, Matsui T, Ito K, Korenaga M, Imamura M, Masaki N, Mizokami M.	Ex vivo induction of IFN-λ3 by a TLR7 agonist determines response to Peg-IFN/Ribavirin therapy in chronic hepatitis C patients.	J Gastroenterol	49	126-137	2014
Sunbul M, Khan A, Kurbanov F, Leblebicioglu H, <u>Sugiyama M</u> , Tanaka Y, Mizokami M.	Tracing the Spread of Hepatitis C Virus in Turkey: A Phylogenetic Analysis.	Intervirology	56	201-205	2013
<u>Yoshio S</u> , Kanto T, Kuroda S, Matsubara T, Higashitani K, Kakita N, Ishida H, Hiramatsu N, Nagano H, <u>Sugiyama M</u> , Murata K, Fukuhara T, Matsuura Y, Hayashi N, Mizokami M, Takehara T.	Human blood dendritic cell antigen 3 (BDCA3)(+) dendritic cells are a potent producer of interferon-λ in response to hepatitis C virus.	Hepatology	57	1705-1715	2013
Sakamoto T, Tanaka Y, Watanabe T, Iijima S, Kani S, <u>Sugiyama M</u> , Murakami S, Matsuura K, Kusakabe A, Shinkai N, Sugauchi F, Mizokami M.	Mechanism of the dependence of hepatitis B virus genotype G on co-infection with other genotypes for viral replication.	J Viral Hepat.	20	27-36	2013

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Honda S, Miyagi H, Suzuki H, Minato M, Haruta M, Kaneko Y, Hatanaka KC, Hiyama E, Kamijo T, Okada T, <u>Taketomi A.</u>	RASSF1A methylation indicates a poor prognosis in hepatoblastoma patients.	Pediatr Surg Int.	29(11)	1147-52	2013
Wakayama K, Kamiyama T, Yokoo H, Kakisaka T, Kamachi H, Tsuruga Y, Nakanishi K, Shimamura T, Todo S, <u>Taketomi A.</u>	Surgical management of hepatocellular carcinoma with tumor thrombi in the inferior vena cava or right atrium.	World J Surg Oncol.			2013
Shibasaki S, Takahashi N, Toi H, Tsuda I, Nakamura T, Hase T, Minagawa N, Homma S, Kawamura H, <u>Taketomi A.</u>	Percutaneous transhepatic gallbladder drainage followed by elective laparoscopic cholecystectomy in patients with moderate acute cholecystitis under antithrombotic therapy.	J Hepatobiliary Pancreat Sci.			2013
Kamiyama T, Yokoo H, Furukawa J, Kurogochi M, Togashi T, Miura N, Nakanishi K, Kamachi H, Kakisaka T, Tsuruga Y, Fujiyoshi M, <u>Taketomi A.</u> , Nishimura S, Todo S.	Identification of novel serum biomarkers of hepatocellular carcinoma using glycomic analysis.	Hepatology.	57(6)	2314-25	2013
Shirabe K, Motomura T, Takeishi K, Morita K, Kayashima H, <u>Taketomi A.</u> , Ikegami T, Soejima Y, Yoshizumi T, Maehara Y.	Human early liver regeneration after hepatectomy in patients with hepatocellular carcinoma: special reference to age.	Scand J Surg.	102(2)	101-5	2013
Ijichi H, Shirabe K, <u>Taketomi A.</u> , Yoshizumi T, Ikegami T, Mano Y, Aishima S, Abe K, Honda H, Maehara Y.	Clinical usefulness of (18) F-fluorodeoxyglucose positron emission tomography/computed tomography for patients with primary liver cancer with special reference to rare histological types, hepatocellular carcinoma with sarcomatous change and combined hepatocellular and cholangiocarcinoma.	Hepatol Res.	43(5)	481-7	2013

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Shimada S, Kamiyama T, Yokoo H, Wakayama K, Tsuruga Y, Kakisaka T, Kamachi H, <u>Taketomi A</u> .	Clinicopathological characteristics and prognostic factors in young patients after hepatectomy for hepatocellular carcinoma.	World J Surg Oncol.			2013
<u>Taketomi A</u> , Shirabe K, Muto J, Yoshiya S, Motomura T, Mano Y, Ikegami T, Yoshizumi T, Sugio K, Maehara Y.	A rare point mutation in the Ras oncogene in hepatocellular carcinoma.	Surg Today.	43(3)	289-92	2013
Mano Y, Aishima S, Fujita N, Tanaka Y, Kubo Y, Motomura T, <u>Taketomi A</u> , Shirabe K, Maehara Y, Oda Y.	Tumor-associated macrophage promotes tumor progression via STAT3 signaling in hepatocellular carcinoma.	Pathobiology.	80(3)	146	2013
Aketa H, <u>Tatsumi T</u> , Kohga K, Tsunematsu H, Aono S, Shimizu S, Kodama T, Nawa T, Shigekawa M, Hikita H, Sakamori R, Hosui A, Miyagi T, Hiramatsu N, Kanto T, Hayashi N, Takehara T	The combination therapy of $\alpha$ -galactosylceramide and 5-fluorouracil showed antitumor effect synergistically against liver tumor in mice	Int J Cancer	133(5)	1126-1135	2013
Ishida H, Kato T, Takehana K, <u>Tatsumi T</u> , Hosui A, Nawa T, Kodama T, Shimizu S, Hikita H, Hiramatsu N, Kanto T, Hayashi N, Takehara T	Valine, the branched-chain amino acid, suppresses hepatitis C virus RNA replication but promotes infectious particle formation	Biochem Biophys Res Commun	437(1)	127-133	2013
Harada N, Hiramatsu N, Oze T, Yamada R, Kurokawa M, Miyazaki M, Yakushijin T, Miyagi T, <u>Tatsumi T</u> , Kiso S, Kanto T, Kasahara A, Oshita M, Mita E, Hagiwara H, Inui Y, Katayama K, Tamura S, Yoshihara H, Imai Y, Inoue A, Hayashi N, Takehara T.	Incidence of hepatocellular carcinoma in HCV-infected patients with normal alanine aminotransferase levels categorized by Japanese treatment guidelines.	J Gastroenterol	48(4)	535-543	2013

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Komatsu N, Motosugi U, <u>Maekawa S</u> , Shindo K, Sakamoto M, Sato M, Tatsumi A, Miura M, Amemiya F, Nakayama Y, Inoue T, Fukasawa M, Uetake T, Ohtaka M, Sato T, Asahina Y, Kurosaki M, Izumi N, Ichikawa T, Araki T, Enomoto N.	Hepatocellular carcinoma risk assessment using gadoxetic acid-enhanced hepatocyte phase magnetic resonance imaging.	Hepatol Res.	Feb 14	In press	2014
<u>Maekawa S</u> , Enomoto N.	Once-daily simeprevir in combination with pegylated-interferon and ribavirin: a new horizon in the era of direct-acting antiviral agent therapy for chronic hepatitis C.	J Gastroenterol.	Jan;49 (1)	163-4.	2014
Miura M, <u>Maekawa S</u> , Takano S, Komatsu N, Tatsumi A, Asakawa Y, Shindo K, Amemiya F, Nakayama Y, Inoue T, Sakamoto M, Yamashita A, Moriishi K, Enomoto N.	Deep-sequencing analysis of the association between the quasispecies nature of the hepatitis C virus core region and disease progression.	J Virol.	87(23)	12541-51.	2013
Shindo H, <u>Maekawa S</u> , Komase K, Miura M, Kadokura M, Sueki R, Komatsu N, Shindo K, Amemiya F, Nakayama Y, Inoue T, Sakamoto M, Yamashita A, Moriishi K, Enomoto N.	IL-28B (IFN- $\lambda$ 3) and IFN- $\alpha$ synergistically inhibit HCV replication.	J Viral Hepat.	20(4)	281-9.	2013
Komase K, <u>Maekawa S</u> , Miura M, Sueki R, Kadokura M, Shindo H, Shindo K, Amemiya F, Nakayama Y, Inoue T, Sakamoto M, Yamashita A, Moriishi K, Enomoto N.	Serum RANTES level influences the response to pegylated interferon and ribavirin therapy in chronic hepatitis C.	Hepatol Res.	43(8)	865-75.	2013
Yasui Y, Kudo A, Kurosaki M, Matsuda S, Muraoka M, Tamaki N, Suzuki S, Hosokawa T, Ueda K, Matsunaga K, Nakanishi H, Tsuchiya K, Itakura J, Takahashi Y, Tanaka S, <u>Asahina Y</u> , Enomoto N, Arii S, Izumi N	Reduced organic anion transporter expression is a risk factor for hepatocellular carcinoma in chronic hepatitis C patients: a propensity score matching study.	Oncology	86	53-62	2014

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Tsuchiya K, <u>Asahina Y</u> , Tamaki N, Yasui Y, Hosokawa T, Ueda K, Nakanishi H, Itakura J, Kurosaki M, Enomoto N, Izumi N	Risk factors for exceeding the Milan criteria after successful radiofrequency ablation in patients with early stage hepatocellular carcinoma.	Liver Transplant	in press		2013
Tamaki N, Kurosaki M, Matsuda S, Muraoka M, Yasui Y, Suzuki S, Hosokawa T, Ueda K, Tsuchiya K, Nakanishi H, Itakura J, Takahashi Y, <u>Asahina Y</u> , Izumi N	Non-invasive prediction of hepatocellular carcinoma development using serum fibrosis marker in chronic hepatitis C patients.	J Gastroenterol	in press		2013
Sato A, Sata M, Ikeda K, Kumada T, Izumi N, <u>Asahina Y</u> , Osaki Y, Chayama K, Kaneko S, Sakai A, Onji M, Hiasa Y, Omura T, Ozeki I, Yokosuka O, Shiina S, Itsubo M, Nishiguchi S, Hirano K, Ide T, Sakisaka S, Yamasaki T, Hidaka I, Tanaka M, Kim SR, Ichida T	Clinical characteristics of patients who developed hepatocellular carcinoma after hepatitis C virus eradication with interferon therapy: current status in Japan.	Internal Medicine	52	2701-2706	2013
<u>Asahina Y</u> , Tsuchiya K, Nishimura T, Muraoka M, Suzuki Y, Tamaki N, Yasui Y, Hosokawa T, Ueda K, Nakanishi H, Itakura J, Takahashi Y, Kurosaki M, Enomoto N, Nakagawa M, Kakinuma S, Watanabe M, Izumi N	-fetoprotein levels after interferon therapy and risk of hepatocarcinogenesis in chronic hepatitis C.	Hepatology	58	1253-1262	2013
<u>Asahina Y</u> , Tsuchiya K, Nishimura T, Muraoka M, Suzuki Y, Tamaki N, Yasui Y, Hosokawa T, Ueda K, Nakanishi H, Itakura J, Takahashi Y, Kurosaki M, Enomoto N, Nakagawa M, Kakinuma S, Watanabe M, Izumi N	Genetic variation near interleukin 28B and the risk of hepatocellular carcinoma in patients with chronic hepatitis C.	J Gastroenterol	in press		2013

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Asahina Y, Hayashi N, Izumi N, Koike K, Kumada H, Oketani M, Suzuki F, Takikawa H, Tanaka A, Tsubouchi H, Yotsuyanagi H: editors of the Drafting Committee for Hepatitis Management Guidelines.	Guidelines for the Management of Hepatitis C Virus Infection.	Hepatol Res	43	1-34	2013
Tsuchiya K, <u>Asahina Y</u> , Matsuda S, Muraoka M, Nakata T, Suzuki Y, Tamaki N, Yasui Y, Suzuki S, Hosokawa T, Nishimura T, Ueda K, Kuzuya T, Nakanishi H, Itakura J, Takahashi Y, Kurosaki M, Enomoto N, Izumi N	Changes in plasma vascular endothelial growth factor at 8 weeks after sorafenib administration as predictors of survival for advanced hepatocellular carcinoma.	Cancer	120	229-237	2014
Izumi N, <u>Asahina Y</u> , Kurosaki M, Yamada G, Kawai T, Kajiwara E, Okamura Y, Takeuchi T, Yokosuka O, Kariyama K, Toyoda J, Inao M, Tanaka E, Moriwaki H, Adachi H, Katsushima S, Kudo M, Takaguchi K, Hiasa Y, Chayama K, Yatsunashi H, Oketani M, Kumada H	Inhibition of hepatocellular carcinoma by PegIFN $\alpha$ -2a in patients with chronic hepatitis C: a nationwide multicenter cooperative study.	J Gastroenterol	48	382-390	2013
Toyota J, Ozeki I, Karino Y, <u>Asahina Y</u> , Izumi N, Takahashi S, Kawakami Y, Chayama K, Kamiya N, Aoki K, Yamada I, Suzuki Y, Suzuki F, Kumada H	Virological response and safety of 24-week telaprevir alone in Japanese patients infected with hepatitis C virus subtype 1b.	J Viral Hepat	20	167-173	2013
Tamaki N, Kurosaki M, Tanaka K, Suzuki Y, Hoshioka Y, Kato T, Yasui Y, Hosokawa T, Ueda K, Tsuchiya K, Nakanishi H, Itakura J, <u>Asahina Y</u> , Izumi N	Noninvasive estimation of fibrosis progression overtime using the FIB-4 index in chronic hepatitis C.	J Viral Hepat	20	72-76	2013
Nakanishi H, Kurosaki M, Nakanishi K, Tsuchiya K, Noda T, Tamaki N, Yasui Y, Hosokawa T, Ueda K, Itakura J, Anami K, <u>Asahina Y</u> , Enomoto N, Higuchi T, Izumi N	Impaired brain activity in cirrhotic patients with minimal hepatic encephalopathy: Evaluation by near-infrared spectroscopy.	Hepatol Res	in press		2013

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Tamaki N, Kurosaki M, Matsuda S, Nakata T, Muraoka M, Suzuki Y, Yasui Y, Suzuki S, Hosokawa T, Nishimura T, Ueda K, Tsuchiya K, Nakanishi H, Itakura J, Takahashi Y, Matsunaga K, Taki K, <u>Asahina Y</u> , Izumi N	Prospective comparison of real-time tissue elastography and serum fibrosis markers for the estimation of liver fibrosis in chronic hepatitis C patients.	Hepatol Res	in press		2013
<u>Asahina Y</u> , Hayashi N, Izumi N, Koike K, Kumada H, Oketani M, Suzuki F, Takikawa H, Tanaka A, Tsubouchi H, Yotsuyanagi H: editors of the Drafting Committee for Hepatitis Management Guidelines.	JSH Guidelines for the Management of Hepatitis C Virus Infection: A 2014 Update for Genotype 1.	Hepatol Res	44	S59-S70	2014
<u>Asahina Y</u> , Hayashi N, Hiramatsu N, Izumi N, Koike K, Kumada H, Kurosaki M, Oketani M, Suzuki F, Takikawa H, Tanaka A, Tanaka E, Tanaka Y, Tsubouchi H: editors of the Drafting Committee for Hepatitis Management Guidelines.	Guidelines for the Management of Hepatitis B Virus Infection.	Hepatol Res	44	S1-S58	2014
Saito T, Sugimoto M, Igarashi K, Saito K, Shao L, Katsumi T, Tomita K, Sato C, Okumoto K, Nishise Y, Watanabe H, Tomita M, <u>Ueno Y</u> , Soga T.	Dynamics of serum metabolites in patients with chronic hepatitis C receiving pegylated interferon plus ribavirin: A metabolomics analysis.	Metabolism	62 (11)	1577-1586	2013
Sato C, Saito T, Shao L, Okumoto K, Nishise Y, Watanabe H, Makino N, Fukao A, Kitanaka C, Kayama T, <u>Ueno Y</u> , Kawata S.	Impaired mitochondrial $\beta$ -oxidation in patients with chronic hepatitis C: relation with viral load and insulin resistance.	BMC Gastroenterol	13	112-119	2013
Ishii R, Saito T, Shao L, Okumoto K, Nishise Y, Watanabe H, Makino N, Fukao A, Kitanaka C, Kayama T, <u>Ueno Y</u> , Kawata S.	Serum prolactin levels and prolactin mRNA expression in peripheral blood mononuclear cells in hepatitis C virus infection.	J Med Virol	85 (7)	119-1205	2013
奥本和夫、斎藤貴史、勝見智大、富田恭子、佐藤智佳子、阿蘇里佳、西瀬雄子、渡辺久剛、 <u>上野義之</u>	アボ型 ALT により ALT が異常低値を示した C 型慢性肝炎に対して抗ウイルス療法を行った一例	肝臓	54 (8)	543-547	2013

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
渡辺久剛、 <u>上野義之</u> .	B型肝炎の自然予後 (無治療住民検診での長期予後)	肝胆膵	66(3)	399-407	2013
Fujino T, Aoyagi Y, Takahashi M, Yada R, Yamamoto N, Ohishi Y, Nishiura A, Kohjima M, Yoshimoto T, Fukuizumi K, Nakashima M, Kato M, Kotoh K, <u>Nakamuta M</u> , Enjoji M.	Association of ITPA polymorphism with outcomes of peginterferon- $\alpha$ plus ribavirin combination therapy.	World J Gastrointest Pharmacol Ther.	4(3)	54-60	2013
Ogawa E, Furusyo N, <u>Nakamuta M</u> , Kajiwara E, Nomura H, Dohmen K, Takahashi K, Satoh T, Azuma K, Kawano A, Tanabe Y, Kotoh K, Shimoda S, Hayashi J; Kyushu University Liver Disease Study (KULDS) Group.	Clinical milestones for the prediction of severe anemia by chronic hepatitis C patients receiving telaprevir-based triple therapy.	J Hepatol.	59(4)	667-74	2013
Furusyo N, Ogawa E, <u>Nakamuta M</u> , Kajiwara E, Nomura H, Dohmen K, Takahashi K, Satoh T, Azuma K, Kawano A, Tanabe Y, Kotoh K, Shimoda S, Hayashi J; Kyushu University Liver Disease Study (KULDS) Group.	Telaprevir can be successfully and safely used to treat older patients with genotype 1b chronic hepatitis C.	J Hepatol.	59(2)	205-12	2013
Ogawa E, Furusyo N, Kajiwara E, Takahashi K, Nomura H, Maruyama T, Tanabe Y, Satoh T, <u>Nakamuta M</u> , Kotoh K, Azuma K, Dohmen K, Shimoda S, Hayashi J; Kyushu University Liver Disease Study (KULDS) Group.	Efficacy of pegylated interferon alpha-2b and ribavirin treatment on the risk of hepatocellular carcinoma in patients with chronic hepatitis C: a prospective, multicenter study.	J Hepatol.	58(3)	495-501.	2013

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Sasaki Y, Shimonaka Y, Ikuta K, Hosoki T, Sasaki K, Torimoto Y, Kanada H, Moriguchi Y, <u>Kohgo Y.</u>	Hepcidin production in response to iron is controlled by monocyte-derived humoral factors.	Int J Hematol	99(1)	12-20	2014
Ichiki K, Ikuta K, Addo L, Tanaka H, Sasaki Y, Shimonaka Y, Sasaki K, Ito S, Shindo M, Ohtake T, Fujiya M, Torimoto Y, <u>Kohgo Y.</u>	Upregulation of iron regulatory hormone hepcidin by interferon a.	J Gastroenterol Hepatol	29(2)	387-394	2014
Suzuki Y, Ohtake T, Nishiguchi S, Hashimoto E, Aoyagi Y, Onji M, <u>Kohgo Y.</u> ; Japan Non-B, Non-C Liver Cirrhosis Study Group.	Survey of non-B, non-C liver cirrhosis in Japan.	Hepatol Res	43(10)	1020-31	2013
Yoneda M, Imajo K, Eguchi Y, Fujii H, Sumida Y, Hyogo H, Ono M, Suzuki Y, Kawaguchi T, Aoki N, Sata M, Kanemasa K, <u>Kohgo Y.</u> , Saibara T, Chayama K, Itoh Y, Yoshikawa T, Anzai K, Fujimoto K, Okanoue T, Nakajima A; Japan Study Group of Nonalcoholic Fatty Liver Disease (JSG-NAFLD).	Noninvasive scoring systems in patients with nonalcoholic fatty liver disease with normal alanine aminotransferase levels.	J Gastroenterol	48(9)	1051-60	2013
Shima T, Uto H, Ueki K, Takamura T, <u>Kohgo Y.</u> , Kawata S, Yasui K, Park H, Nakamura N, Nakatou T, Tanaka N, Umemura A, Mizuno M, Tanaka J, Okanoue T.	Clinicopathological features of liver injury in patients with type 2 diabetes mellitus and comparative study of histologically proven nonalcoholic fatty liver diseases with or without type 2 diabetes mellitus.	J Gastroenterol	48(4)	515-25	2013

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Tanaka S, <u>Miyanishi K</u> , Kobune M, Kawano Y, Hoki T, Kubo T, Hayashi T, Sato T, Sato Y, Takimoto R, Kato J	Increased hepatic oxidative DNA damage in patients with nonalcoholic steatohepatitis who develop hepatocellular carcinoma.	J Gastroenterol.	48(11)	1249-58	2013

「研究成果の刊行に関する別刷り」